Lexicon Pharma (LXRX) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Sanofi and Lexicon Pharmaceuticals To Collaborate on Sotagliflozin, an Investigational New Oral Medicine for People with Diabetes
November 6, 2015 8:00 AM ESTPARIS and THE WOODLANDS, Texas, Nov. 6, 2015 /PRNewswire/ -- Sanofi and Lexicon Pharmaceuticals (NASDAQ: LXRX), Inc. announced today that they have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for people with diabetes.
"This agreement with Lexicon reinforces our commitment to helping people living with diabetes," said Pascale Witz, Executive Vice President, Sanofi, who will lead the Global Diabetes and Cardiovascular Care Business Unit in the... More
Lexicon Pharmaceuticals Reports 3rd Quarter Financial Results And Discusses Collaboration With Sanofi For Sotagliflozin
November 6, 2015 6:00 AM ESTTHE WOODLANDS, Texas, Nov. 6, 2015 /PRNewswire/ --Â Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the third quarter ended September 30, 2015 and provided an overview of key milestones for the company's lead drug candidates.
Earlier today, Lexicon announced that it entered into a collaboration and license agreement with Sanofi for the worldwide... More
